ArticleBrain pathology (Zurich, Switzerland)2020
Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease.
Article in Brain pathology (Zurich, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Comorbid pathologies and their impact on multiple system atrophy: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Spatially resolved molecular signatures of Lewy body dementia.Acta neuropathologica · 2026Article
- Targeting protein aggregate co-pathologies in neurodegeneration: a viable therapeutic strategy?Molecular neurodegeneration advances · 2026Review
- Genetic Modifiers of Parkinson's Disease: A Case-Control Study.Annals of clinical and translational neurology · 2025Observational
- Autonomic dysfunction in multiple system atrophy: from pathophysiology to clinical manifestations.Annals of medicine · 2025Review
- Limbic Alzheimer's co-pathology in multiple system atrophy is associated with cognitive impairment and diagnostic inaccuracy.Acta neuropathologica · 2025Article
- Modeling Lewy body disease withScience advances · 2024Article
- A Patient with Multiple System Atrophy-Parkinsonian Type Presenting with Progressive Micrographia.Asian journal of neurosurgery · 2024Article
- Frequency of Comorbid Pathologies and Their Clinical Impact in Multiple System Atrophy.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Clinical and Genetic Features of Multiplex Families with Multiple System Atrophy and Parkinson's Disease.Cerebellum (London, England) · 2024Article
- Multiple system atrophy with amyloid-β-predominant Alzheimer's disease neuropathologic change.Brain communications · 2024Article
- Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank.Neurology · 2023Article
- REM Behavior Disorder: Implications for PD Therapeutics.Current neurology and neuroscience reports · 2023Review
- Threonine Cavities Are Targetable Motifs That Control Alpha-Synuclein Fibril Growth.ACS chemical neuroscience · 2022Article
- Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.Acta neuropathologica communications · 2022Article
- Heterogeneity of Multiple System Atrophy: An Update.Biomedicines · 2022Review
- Passive Immunization in Alpha-Synuclein Preclinical Animal Models.Biomolecules · 2022Review
- Multiple system atrophy variant with severe hippocampal pathology.Brain pathology (Zurich, Switzerland) · 2022Article
- Determinants of cognitive impairment in multiple system atrophy: Clinical and genetic study.PloS one · 2022Article
- A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson's disease with dementia.Brain communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundAbnormal aggregates of α-synuclein are pathologic hallmarks of multiple system atrophy (MSA) and Lewy body disease (LBD). LBD sometimes coexists with MSA, but the impact of co-pathology, particularly diffuse LBD, on presentation of MSA has not been studied. We aimed to determine the frequency and clinicopathologic features of MSA with LBD (MSA+LBD).
methodsUsing hematoxylin & eosin and α-synuclein-immunostained slides, we assessed the distribution and severity of LBD in 230 autopsy-confirmed MSA patients collected from 1998 to 2018. Alzheimer-type pathology was assessed to assign the likelihood of clinical presentations of dementia with Lewy body (DLB) using the consensus criteria for DLB. We reviewed medical records to characterize clinicopathologic features of MSA+LBD. Genetic risk factors for LBD, including APOE ε4 allele and mutations in GBA, SNCA, LRRK2, and VPS35, were analyzed.
resultsLBD was observed in 11 MSA patients (5%); seven were brainstem type, three were transitional type, and one was diffuse type. The latter four had an intermediate or high likelihood of DLB. Three of the four had an antemortem diagnosis of Parkinson's disease with dementia (PDD) or clinically probable DLB. Two patients had neuronal loss in the substantia nigra, but not in striatal or olivocerebellar systems with widespread glial cytoplasmic inclusions, consistent with minimal change MSA. In these cases, LBD was considered the primary pathology, and MSA was considered coincidental. APOE ε4 allele frequency was not different between MSA+LBD and MSA without LBD. Two of nine MSA+LBD patients had a risk variant of GBA (p.T408M and p.E365K).
conclusionsAlthough rare, MSA with transitional or diffuse LBD can develop clinical features of PDD or DLB. Minimal change MSA can be interpreted as a coincidental, but distinct, α-synucleinopathy in a subset of patients with diffuse LBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.